Delphi advisor to AddLife AB (publ) in connection with oversubscribed rights issue of SEK 500 million
Delphi has acted as legal advisor to AddLife in connection with a rights issue for which the subscription period ended on 15 February 2019. Through the rights issue AddLife will receive proceeds amounting to approximately SEK 500 million.
The final count shows that 142,901 A-shares and 3,357,585 B-shares, corresponding to approximately 99.3 percent of the offered shares, were subscribed for with subscription rights. The remaining 1,637 A-shares and 24,636 B-shares that were not subscribed for with subscription rights have been allocated to those who have applied for subscription of shares without subscription rights in accordance with the principles described in the prospectus. Interest in the rights issue has been high and as a result the rights issue was oversubscribed by 68 percent.
AddLife is an independent player within Life Science. They offer high-quality products, services and advice to both the private and public sectors, mainly in healthcare services, research, universities and colleges, as well as to the food and pharmaceutical industries. The group develops and acquires profitable companies in selected niche areas in the segments diagnostics, biomedical research and laboratory analysis and medtech.
Delphi’s team consisted of Mats Dahlberg as responsible partner, assisted by Matilda Karlsson, Emil Blomqvist and Fredrik Nykvist. For more information, see AddLife’s press release: www.add.life.